Search research articles
Contact Us
Filters
Showing results (181-190 of 217) with videos related to
Page
of 22
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 26, 2024
Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Elisa Yaniz-Galende, Qinghe Zeng, Juan F Bejar-Grau, et al.
NPJ Genomic Medicine
|
April 23, 2026
Immuno-molecular features associated with exceptional recurrence-free survivorship from Ovarian Cancer in the pre-PARP era
Félix Blanc-Durand, Elisa Yaniz Galende, Gwénaël Ferron, et al.
Gynecologic Oncology
|
March 23, 2021
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2
Gottfried E Konecny, Amit M Oza, Anna V Tinker, et al.
Journal of the National Cancer Institute
|
March 11, 2021
Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer
Cathalijne C B Post, Ellen Stelloo, Vincent T H B M Smit, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 19, 2025
Association between molecular classification and overall survival in patients with metastatic endometrial carcinoma: ancillary results of the UTOLA phase II GINECO trial
Guillaume Beinse, Karen Leroy, Pierre-Alexandre Just, et al.
Cancers
|
March 10, 2022
Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial
Jean-David Fumet, Emilie Lardenois, Isabelle Ray-Coquard, et al.
Gynecologic Oncology
|
August 31, 2020
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma
Nicoletta Colombo, Amit M Oza, Domenica Lorusso, et al.
Gynecologic Oncology
|
September 9, 2017
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
Amit M Oza, Anna V Tinker, Ana Oaknin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 19, 2026
No prognostic role for FIGO grading in mismatch repair deficient endometrial carcinoma
Famke C Wakkerman, Cathalijne C B Post, Gitte Ørtoft, et al.
BMC Cancer
|
July 29, 2024
Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer : Alexandra Leary
Alexandra Leary, Purificación Estévez-García, Renaud Sabatier, et al.
Page
of 22
Search research articles
Search
Showing results (181-190 of 217) with videos related to
Sort By:
Page
of 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 26, 2024
Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Elisa Yaniz-Galende, Qinghe Zeng, Juan F Bejar-Grau, et al.
NPJ Genomic Medicine
|
April 23, 2026
Immuno-molecular features associated with exceptional recurrence-free survivorship from Ovarian Cancer in the pre-PARP era
Félix Blanc-Durand, Elisa Yaniz Galende, Gwénaël Ferron, et al.
Gynecologic Oncology
|
March 23, 2021
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2
Gottfried E Konecny, Amit M Oza, Anna V Tinker, et al.
Journal of the National Cancer Institute
|
March 11, 2021
Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer
Cathalijne C B Post, Ellen Stelloo, Vincent T H B M Smit, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 19, 2025
Association between molecular classification and overall survival in patients with metastatic endometrial carcinoma: ancillary results of the UTOLA phase II GINECO trial
Guillaume Beinse, Karen Leroy, Pierre-Alexandre Just, et al.
Cancers
|
March 10, 2022
Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial
Jean-David Fumet, Emilie Lardenois, Isabelle Ray-Coquard, et al.
Gynecologic Oncology
|
August 31, 2020
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma
Nicoletta Colombo, Amit M Oza, Domenica Lorusso, et al.
Gynecologic Oncology
|
September 9, 2017
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
Amit M Oza, Anna V Tinker, Ana Oaknin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 19, 2026
No prognostic role for FIGO grading in mismatch repair deficient endometrial carcinoma
Famke C Wakkerman, Cathalijne C B Post, Gitte Ørtoft, et al.
BMC Cancer
|
July 29, 2024
Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer : Alexandra Leary
Alexandra Leary, Purificación Estévez-García, Renaud Sabatier, et al.
Page
of 22